IP Library Granted Patent US 9,295,686
Granted Patent B2
US 9,295,686 · App. 14/067,116 · Granted Mar 29, 2016

Treatment of cancers with A-8R peptide

Inventors: Lirim Shemshedini (Ypsilanti, MI); Shao-Yong Chen (Brookline, MA); Changmeng Cai (Newton, MA); Chen-Lin Hsieh (Brighton, MA)
Assignee: The University of Toledo
A61K31/7048A61K38/08A61K38/10C07K7/06C07K7/08A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,295,686
App. No.
14/067,116
Granted
Mar 29, 2016
Kind
B2
Abstract

The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.

Claims (7)

1. A method to treat a patient with hormone-refractory prostate cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:1 to the patient.

2. A method to treat a patient with metastatic prostate cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:1 to the patient.

3. A method to treat a patient with late stage prostate cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:1 to the patient.

4. A method to treat a patient with an sCGa1-expressing pancreatic cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:1 to the patient.

5. A method to treat a patient with an sCGa1-expressing gastrointestinal cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:1 to the patient.

6. A method to treat a patient with an sCGa1-expressing cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:1 to the patient,

wherein the cancer is selected from the group consisting of: neuroblastoma; lung cancer; bile duct cancer; non small cell lung carcinoma; hepatocellular carcinoma; nasopharyngeal carcinoma; gastric cancer; colon cancer; uterine cervical carcinoma; gall bladder cancer; prostate cancer; breast cancer; testicular germ cell tumors; colorectal cancer; glioma; thyroid cancer; basal cell carcinoma; gastrointestinal stromal cancer; hepatoblastoma; endometrial cancer; ovarian cancer; and urothelial cancer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 5, 2014
From: UNIVERSITY OF TOLEDO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032387/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2013
From: SHEMSHEDINI, LIRIM; CHEN, SHAO-YONG; CAI, CHANGMENG; HSIEH, CHEN-LIN
To: THE UNIVERSITY OF TOLEDO
Reel/Frame 031512/0481 →
Continuity (3)
Division 13375307
Provisional Application 61182712 · May 30, 2009
Related Publication 20140057852A1 · Feb 27, 2014